16 completed, 2 not yet recruiting, 2 terminated, 1 recruiting. 21 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Completed 16, Not yet recruiting 2, Terminated 2, Recruiting 1 |
| Phase 3 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Lymphoma Study Association: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations Ibrutinib Oral Tablet, Venetoclax Oral Tablet, Epcoritamab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | 44 | 2026-12-31 | 2026-07-31 |
| Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Zanubrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | 95 | 2026-12-01 | 2026-09-14 |
| Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse golcadomide - Diffuse Large B-cell Lymphoma Refractory, Refractory Primary Mediastinal Large B-Cell Lymphoma | Phase 2 | Recruiting | The Lymphoma Academic Research Organisation | 65 | 2024-06-14 | 2026-06-04 |
| Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma Tislelizumab - Classical Hodgkin Lymphoma | Phase 2 | Completed | BeiGene | 46 | 2020-08-20 | 2025-09-24 |
| Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients Nivolumab, Rituximab, Gemcitabine - Lymphoma, Non-Hodgkin | Phase 2 / Phase 3 | Completed | Universität des Saarlandes | 348 | 2017-12-05 | 2025-01-28 |
| Study of Mantle Cell Lymphoma Treatment by RiBVD RiBVD - Mantle Cell Lymphoma | Phase 2 | Completed | French Innovative Leukemia Organisation | 76 | 2011-10-01 | 2016-03-16 |
| Lenalidomide and R-CHOP in B-cell Lymphoma Lenalidomide and R-CHOP - Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma | Phase 1 / Phase 2 | Completed | Lymphoma Study Association | 108 | 2009-01-06 | 2018-08-23 |
| Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan), ASCT, Rituximab - Lymphoma, Large Cell, Diffuse | Phase 2 | Completed | Lymphoma Study Association | 75 | 2007-08-01 | 2018-03-07 |
| Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis Rituximab, Cytarabine - Lymphoma, Non-Hodgkin, Diffuse Large B-cell Lymphoma | Phase 2 | Completed | Lymphoma Study Association | 60 | 2007-07-01 | 2018-08-23 |
| Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma ZARNESTRA (Tipifarnib) - Mantle Cell Lymphoma | Phase 2 | Terminated | Lymphoma Study Association | 11 | 2007-06-01 | 2018-08-23 |
| Mini-CHOP and Rituximab in Patients Aged Over 80 Years R mini CHOP - Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | Lymphoma Study Association | 150 | 2006-04-01 | 2019-08-26 |
| Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma Velcade, Doxorubicin, Prednisone - Peripheral T-cell Lymphoma | Phase 2 | Completed | Lymphoma Study Association | 60 | 2006-01-08 | 2018-08-23 |
| A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma Rituximab, Prednisone, Doxorubicine - Untreated T-cell Angioimmunoblastic Lymphoma | Phase 2 | Completed | Lymphoma Study Association | 27 | 2005-12-01 | 2017-03-13 |
| A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma Bortezomib - Follicular Lymphoma | Phase 2 | Terminated | Lymphoma Study Association | 87 | 2005-09-01 | 2010-10-26 |
| Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma Zevalin plus BEAM - B-Cell Lymphoma | Phase 2 | Completed | Lymphoma Study Association | 75 | 2005-03-01 | 2006-09-08 |
| Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma Rituximab -CHOP plus Velcade - B Cell Lymphoma | Phase 2 | Completed | Lymphoma Study Association | 48 | 2005-01-01 | 2018-08-23 |
| Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma Rituximab + ACVBP regimen plus Pegfilgrastim, Autologous stem cell transplant - Untreated CD20-positive Large B-cell Lymphoma | Phase 2 | Completed | Lymphoma Study Association | 60 | 2004-05-01 | 2018-08-23 |
| ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma rituximab, doxorubicin, cyclophosphamide - Diffuse Large Cell Lymphoma | Phase 2 | Completed | Lymphoma Study Association | 128 | 2003-12-01 | 2015-09-02 |
| Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX) - Diffuse Large Cell Lymphoma | Phase 2 | Completed | Lymphoma Study Association | 49 | 2003-04-01 | 2015-09-02 |
| Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma rituximab, fludarabine, mitoxantrone - Follicular Lymphoma | Phase 2 | Completed | Lymphoma Study Association | 50 | 2001-04-01 | 2019-08-28 |
Showing 20 of 21. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (8) · Lymphoma (6) · Lymphoma, B-Cell (4) · Lymphoma, Follicular (3) · Lymphoma, Mantle-Cell (3) · Recurrence (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Dendritic Cell Sarcoma, Interdigitating (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, T-Cell, Peripheral (1)
Rituximab (8) · Cyclophosphamide (4) · Doxorubicin (4) · Bortezomib (3) · Cytarabine (2) · Prednisone (2) · ibritumomab tiuxetan (2) · Bleomycin (1) · Carmustine (1) · Etoposide (1) · Gemcitabine (1) · LNH 87 protocol (1) · Lenalidomide (1) · Melphalan (1) · Mitoxantrone (1)
France (18) · Belgium (8) · Switzerland (2) · Australia (1) · Austria (1) · Germany (1) · Israel (1) · Netherlands (1) · Poland (1) · Portugal (1) · United States (1)
Corinne Haioun, MD (4) · Bertrand Coiffier, MD (2) · Christian Gisselbrecht, MD (2) · Alain Delmer, MD (1) · Bertrand Joly, MD (1) · Christian Gisselbrecht, MD PHD (1) · Christophe Fruchart, MD (1)
PMID 26373676, PMID 27282998, PMID 21482186, PMID 21546499, PMID 23753028, PMID 25072780
2025 (2), 2005 (1), 2019 (1)